Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

3.57
+0.24007.21%
Post-market: 3.570.00000.00%16:10 EDT
Volume:2.76M
Turnover:9.64M
Market Cap:588.74M
PE:7.30
High:3.59
Open:3.38
Low:3.36
Close:3.33
52wk High:3.91
52wk Low:0.4000
Shares:164.91M
Float Shares:129.96M
Volume Ratio:1.73
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4890
EPS(LYR):0.3774
ROE:108.21%
ROA:16.13%
PB:4.91
PE(LYR):9.46

Loading ...

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 30

CytomX Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Rachael Lester

Reuters
·
Oct 30

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

TIPRANKS
·
Oct 27

CytomX Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Oct 22

CytomX Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Oct 21

CytomX Therapeutics (CTMX) Gets a Buy from Barclays

TIPRANKS
·
Oct 21

CytomX Names Rachael Lester as Chief Business Officer

MT Newswires Live
·
Oct 21

Press Release: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Dow Jones
·
Oct 21

Oppenheimer positive on CytomX after Merus colon cancer data

TIPRANKS
·
Oct 15

CytomX Therapeutics Up Nearly 10%, on Track for Highest Close Since May 2024 -- Data Talk

Dow Jones
·
Sep 30

Why CytomX Therapeutics Stock Was Skyrocketing This Week

Motley Fool
·
Sep 26

CytomX Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22

Cantor Fitzgerald Initiates CytomX Therapeutics at Overweight With $6 Price Target

MT Newswires Live
·
Sep 22

CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKM

TIPRANKS
·
Sep 17

CytomX Therapeutics Coverage Assumed by Barclays at Overweight

Dow Jones
·
Sep 17

CytomX Therapeutics assumed with an Overweight at Barclays

TIPRANKS
·
Sep 17

CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire
·
Aug 28

CytomX Therapeutics Unveils PROBODY® Platform Advancements Targeting Unmet Oncology Needs in Recent Corporate Presentation

Reuters
·
Aug 16

BRIEF-CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study

Reuters
·
Aug 13

CytomX Therapeutics Inc - Single Grade 5 Treatment-Related Acute Kidney Injury Reported in Cx-2051 Study

THOMSON REUTERS
·
Aug 13